• SPX
  • $5,740.67
  • 0.49 %
  • $27.98
  • DJI
  • $41,938.14
  • 0.34 %
  • $143.54
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,158.08
  • -0.32 %
  • -$26.16
  • IXIC
  • $18,313.63
  • 0.73 %
  • $133.65
Arcellx, Inc. (ACLX) Stock Price, News & Analysis

Arcellx, Inc. (ACLX) Stock Price, News & Analysis

Currency in USD Disclaimer

$82.15

-$4.29

(-4.96%)

Day's range
$77
Day's range
$86
50-day range
$64.1
Day's range
$97.54
  • Country: US
  • ISIN: US03940C1009
52 wk range
$43.5
Day's range
$97.54


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 11.03
  • Piotroski Score 5.00
  • Grade Buy
  • Symbol (ACLX)
  • Company Arcellx, Inc.
  • Price $82.15
  • Changes Percentage (-4.96%)
  • Change -$4.29
  • Day Low $77.00
  • Day High $86.00
  • Year High $97.54

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/11/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $70.00
  • High Stock Price Target $122.00
  • Low Stock Price Target $32.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.03
  • Trailing P/E Ratio -49.3
  • Forward P/E Ratio -49.3
  • P/E Growth -49.3
  • Net Income $-70,690,000

Income Statement

Quarterly

Annual

Latest News of ACLX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

  • Arcellx (ACLX) Surged in Q3. Here's Why

    Baron Funds' "Baron Health Care Fund" Q3 2024 investor letter revealed a 5.81% appreciation. The top holding, Arcellx, Inc. (NASDAQ:ACLX), a biotech company focusing on cell therapies, showed signific...

    By Yahoo! Finance | 4 days ago
  • Here's Why Arcellx (ACLX) Slipped in Q2

    Baron Funds' "Baron Health Care Fund" Q2 2024 investor letter reported a 2.55% decline compared to benchmarks. The fund highlighted Arcellx, Inc. (NASDAQ:ACLX) as a top pick, with significant growth p...

    By Yahoo! Finance | 3 months ago
  • Insider Sale: CFO Michelle Gilson Sells 12,877 Shares of Arcellx Inc (ACLX)

    Michelle Gilson, CFO of Arcellx Inc (NASDAQ:ACLX), sold 12,877 shares on June 26, 2024, now owning 6,915 shares. The biotech company focuses on cell therapies for cancer and autoimmune diseases....

    By Yahoo! Finance | 4 months ago
Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.